Manufacturing

The new excipients manufacturing facility is expected to be completed in 2025.

The collaboration between Samsung Biologics and Pfizer will focus on long-term biosimilars manufacturing.

Webinar Date/Time: Tuesday, June 27th, 2023 at 8am EDT | 1pm BST | 2pm CEST | 5am PDT Wednesday, June 28th, 2023 at 8am EDT | 1pm BST | 2pm CEST | 5am PDT Thursday, June 29th, 2023 at 8am EDT | 1pm BST | 2pm CEST | 5am PDT

invoX Pharma has made a second tranche of investment in pHion Therapeutics to support further development of next-generation mRNA vaccines.

Manufacturers must figure out how flexible they need to be to meet the numerous new requirements of the changing therapeutic and regulatory landscapes.

Makers of specialty biologics, gene therapies, and other personalized medicines are working to identify and reduce potential supply chain risks both upstream and downstream.

Vaccine nationalism strengthens viruses and poses deadly risks for all involved.

The ROSS Model HSM-405SC-25 Inline High Shear Mixer with solids/liquid injection manifold (SLIM) Technology is designed for production floors that require flexibility.

The Agilent 8697 Headspace Sampler -XL Tray features improvements to capacity and ease-of-use.

PSG Biotech’s BioProTT FlowSU System is a next-generation flow-measurement system intended for single-use biopharma applications.

Catalent’s ProteoSuite Oral platform is designed for optimized selection of orally developable targeted protein degrader candidates.

Webinar Date/Time: Wed, Jul 19, 2023 1:00 PM EDT

WuXi Biologics is expanding its manufacturing capacity for drug substance and drug product at its sites in Leverkusen and Wuppertal, Germany.

The start of production of US engineering batches of NXC-201, a CAR-T cell therapy candidate in early clinical development, is the first step in transferring Nexcella’s existing manufacturing process to the United States.

API supplier Olon has started construction of a new manufacturing facility in Milan, Italy, which will be dedicated to production of cytotoxic payloads and linkers for ADCs.

Webinar Date/Time: Wed, Jun 21, 2023 2:00 PM EDT

Webinar Date/Time: Thursday June 29, 2023 at 2pm EDT | 1pm CDT | 11am PDT

Webinar Date/Time: Thu, Jun 15, 2023 11:00 AM EDT

Myrna Wilson, director, Global Marketing, Strategic Growth and Technical Sales, Pharmaceutical Ingredients, Univar Solutions, discusses the state of the biopharma supply chain, movements in the patent industry, and more.

This agreement is intended to be executed and see the impact of any financial transfers by the fiscal year ending March 31, 2024.

Andrea Lodetti, CEO of Bormioli Pharma, an Italian pharma primary packaging manufacturer, speaks about his company's approach to the US market, supply chain instabilities, sustainability, and more.

The new CGMP facility is expected to contribute to the development of mRNA therapeutics, with a building designed for the CGMP manufacture of mRNA-based in-vivo gene editing, gene-edited cell therapies, protein replacement therapies, cancer vaccines, and infectious disease vaccines.

The facility is based on a state-of-the-art design concept that allows maximum flexibility for a multi-product, multi-platform offering.

uBriGene Biosciences will acquire Mustang Bio’s Worcester, Mass., CGT manufacturing facility in a deal worth up to $11 million, expanding its operations into the US market.

Felicity Thomas, European/Senior Editor, Pharm Tech Group, and Andy Dumelow, Head of Technical Sales, I Holland, chat about tablet tooling maintenance in this brief podcast.

Jane True, vice-president of mRNA Commercial Strategy & Innovation and Global Pandemic Security Lead, Pfizer, shares her perspective on how mRNA will shift commercial models in the pharmaceutical industry.

CATTI has launched an in-person training site at the University of Guelph in Ontario, Canada, for training personnel in cell and gene therapy manufacturing.

The new method was developed to isolate tissue-specific EVs from the blood in addition to using a workflow to analyze their diverse multi-omics content.

Synthego has opened its new GMP-compliant RNA manufacturing facility in Redwood City, Calif., for CRISPR-enabled genomics therapeutics.

The first CleanCap analog was launched in 2017, and since then, the capping technology has been incorporated in one of the first commercially approved COVID-19 vaccines.